newsfilter
← Latest News
GlobeNewswire·

Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

Tovecimig (DLL4 x VEGF-A bispecific antibody) met the primary endpoint in the ongoing randomized Phase 2/3 Study in patients with biliary tract cancer (BTC). Achieved a 17.1% overall response rate (ORR), including